Table 3.
Summary of associations between clinicopathological characteristics and methylation for which p≤0.05
| Characteristics | Locus1 | Median PMR2 | p-value3 | |
|---|---|---|---|---|
| Gender |
Male (n=42; 41)4 |
Female (n=9; 6)4 |
||
| MT1A | 153 | 91 | 0.048 | |
| MT2A | 10 | 25 | 0.006 | |
| SFRP4 | 1 | 3 | 0.022 | |
| Histology |
Mixed/Sarcomatoid (n=13) |
Epithelioid (n=35) |
||
| MT2A | 7 | 13 | 0.017 | |
| Asbestos Exposure |
Exposed (n=39) |
Not Exposed (n=10) |
||
| MT1A | 151 | 93 | 0.050 | |
| MT2A | 10 | 21 | 0.018 | |
| Lymph Node Involvement |
Involved (n=38; 37)4 |
Not Involved (n=11; 10)4 |
||
| MT1A | 162 | 106 | 0.047 | |
| SOCS4 | 3 | 1 | 0.005 | |
1
HUGO nomenclature;
2
For SFRP4 and SOCS4 value is median of all positive samples;
3
Mann-Whiteny U test;
4
SFRP4 methylation was available for 41 males and 6 females; SOCS4 methylation data was available for 47 cases.